# KALA BIO, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/KALA BIO, Inc). ## Overview KALA BIO, Inc. is a U.S.-based clinical-stage ophthalmology company focused on developing biologic therapies for serious eye diseases. Its current pipeline centers on KPI-012 for persistent corneal epithelial defect (PCED) and KPI-014 for other ocular indications, following the 2022 sale of its commercial eye-care business to Alcon. ## Products & services • KPI-012 for persistent corneal epithelial defect (PCED) • KPI-014 preclinical program for ocular diseases • MSC-S platform for biologic eye-disease candidates • Clinical development and regulatory advancement of ophthalmic biologics • Potential future commercialization in the U.S. and select ex-U.S. markets - **Lead clinical candidate** (80%) — KPI-012 is the company’s main therapeutic asset being developed for PCED and potentially other ocular indications. - **Preclinical pipeline** (10%) — KPI-014 includes early-stage research aimed at expanding the company’s ophthalmology pipeline. - **Platform technology** (10%) — MSC-S is the underlying cell-based/biologic platform used to generate ophthalmic product candidates. - KPI-012 for persistent corneal epithelial defect (PCED) - KPI-014 preclinical program for ocular diseases - MSC-S platform for biologic eye-disease candidates - Clinical development and regulatory advancement of ophthalmic biologics - Potential future commercialization in the U.S. and select ex-U.S. markets ## Customers KALA BIO does not currently sell commercial products; its near-term customers would be ophthalmologists, eye-care specialists, and the patients they treat if KPI-012 is approved. The company also depends on third-party payors and government reimbursement systems, because coverage and pricing will shape adoption in the U.S. and abroad. - **Ophthalmologists and cornea specialists** (primary) — Would prescribe KPI-012 if approved for PCED or related ocular indications, based on clinical efficacy and ease of use. - **Patients with persistent corneal epithelial defect** (primary) — End users of the therapy; demand is driven by unmet need in difficult-to-heal corneal disease. - **Third-party payors** (primary) — Commercial and government payors would determine access through coverage, pricing, and reimbursement. - **Ex-U.S. commercial partners** (secondary) — Potential collaborators for distribution, co-promotion, or licensing in non-U.S. markets. - Ophthalmologists treating PCED and other corneal disorders - Patients with serious ocular surface disease needing advanced therapy - Third-party payors that determine coverage and reimbursement - Government health systems in markets where approval is pursued - Potential licensing or distribution partners outside the U.S. ## Geography The company is headquartered in the United States and expects initial commercialization efforts, if approved, to be centered there with a small targeted sales force. Management has also indicated it may pursue select non-U.S. markets through partners, which would reduce direct operating footprint but also lower economics versus self-commercialization. - United States is the core market for KPI-012 development and launch - Potential ex-U.S. markets may be served through partners - No disclosed commercial manufacturing footprint in the excerpts - Geography is driven by regulatory approval and reimbursement access - Partner-led international expansion would reduce direct control ## Strategy KALA BIO’s strategy is to advance KPI-012 through clinical development, secure regulatory approval, and then commercialize it either directly in the U.S. or through partnerships. Near term, the company is also focused on preserving liquidity, exploring strategic alternatives, and raising capital to fund operations and development. - **Complete clinical development of KPI-012** (short-term) — The company’s value depends on generating clinical data that can support approval and future commercialization. - **Secure additional financing** (short-term) — Management disclosed substantial doubt about going concern and the need for new capital to continue operations. - **Build a commercialization path** (medium-term) — If approved, the company needs sales, marketing, distribution, and reimbursement capabilities to launch successfully. - Advance KPI-012 clinical development for PCED - Evaluate KPI-012 in additional ocular indications such as LSCD - Pursue regulatory approval and eventual commercialization - Use partnerships for ex-U.S. markets where efficient - Raise capital or pursue strategic transactions to fund operations ## Risks KALA BIO faces the classic risks of a development-stage biotech company, including clinical failure, regulatory delay, reimbursement uncertainty, and heavy dependence on external financing. The company also disclosed acute liquidity and going-concern pressure, making capital access and strategic alternatives especially important to its near-term survival. - **Clinical development failure or delay** [high] — KPI-012 must show favorable results before approval and commercialization can occur. - **Going-concern and liquidity risk** [critical] — Management stated existing resources are not expected to fund operations for at least twelve months. - **Commercialization and reimbursement risk** [high] — Even if approved, the company may struggle to obtain coverage, pricing, and clinician adoption. - **Dependence on third-party financing and strategic transactions** [high] — The company may need equity, debt, partnerships, or asset sales to continue as a going concern. - **Intellectual property and patent challenges** [medium] — Biotech value depends on protecting candidate and platform rights from third-party claims. - Clinical trials may fail or take longer than expected - Regulatory approval for KPI-012 may never be obtained - Reimbursement and pricing could limit adoption after approval - The company may be unable to raise enough capital - Commercial build-out could be costly and delayed - Intellectual property disputes could weaken exclusivity ## Accounting The most important accounting issue is the company’s going-concern assessment, which reflects whether it can continue operations without new funding. Other key judgments include grant accounting for the CIRM award, fair value estimates for warrants and embedded derivatives, stock-based compensation, contingent consideration, and the valuation allowance on deferred tax assets. - **Going concern** — May affect liquidity disclosures, financing assumptions, and investor assessment of survival - **Grant income recognition** — Grant income is matched to R&D expense timing - **Fair value measurements** — Can create non-cash volatility in earnings - **Stock-based compensation** — Affects operating loss and diluted share count analysis - **Deferred tax asset valuation allowance** — May materially affect reported tax expense and equity - Going-concern assessment affects asset and liability presentation - CIRM award is recognized as R&D expense is incurred - Fair value of warrants and embedded derivatives can move earnings - Stock-based compensation is a meaningful non-cash expense - Deferred tax asset valuation allowance depends on future profitability --- *Last updated: 2026-09-24T11:10:58.146286+00:00*